INTERVENTION 1:	Intervention	0
Triple Negative	Intervention	1
ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle.	Intervention	2
ixabepilone	CHEBI:63605	36-47
carboplatin	CHEBI:31355	77-88
INTERVENTION 2:	Intervention	3
HR Positive	Intervention	4
ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle.	Intervention	5
ixabepilone	CHEBI:63605	72-83
carboplatin	CHEBI:31355	113-124
Inclusion Criteria:	Eligibility	0
Male or female patients will be eligible for inclusion in this study if they meet all of the following criteria:	Eligibility	1
male	CHEBI:30780,PATO:0000384	0-4
male	CHEBI:30780,PATO:0000384	10-14
female	PATO:0000383	8-14
Has measurable metastatic and or locally unresectable breast cancer with documented HER2 negative (-) disease	Eligibility	2
breast cancer	DOID:1612	54-67
disease	DOID:4,OGMS:0000031	102-109
Has at least 1 measurable lesion per RECIST criteria (lesions that can be accurately measured in at least 1 dimension (longest diameter (LD) to be recorded) as 20 mm with conventional techniques (CT, MRI, X-ray) or as 10 mm with spiral CT scan). Irradiated lesions cannot be used to assess response but can be used to assess progression.	Eligibility	3
diameter	PATO:0001334	127-135
ct	BAO:0002125	196-198
ct	BAO:0002125	236-238
Has received up to 2 (0 to 2) prior chemotherapy regimens for metastatic disease with the following conditions:	Eligibility	4
disease	DOID:4,OGMS:0000031	73-80
Has had no prior treatment with ixabepilone or platinum agents	Eligibility	5
ixabepilone	CHEBI:63605	32-43
platinum	CHEBI:33364	47-55
Has had no adjuvant chemotherapy within the 6 months prior to study, but may have received prior anthracyclines and/or taxanes as adjuvant chemotherapy	Eligibility	6
adjuvant	CHEBI:60809	11-19
adjuvant	CHEBI:60809	130-138
3 weeks or more have elapsed since last chemotherapy treatment and any related toxicities have resolved to <Grade 1; at least 30 days must have passed since any investigational product has been administered and associated toxicities must have resolved to <Grade 1 (if applicable).	Eligibility	7
product	BAO:0003067	177-184
Has an ECOG Performance Status (PS) 0-2	Eligibility	8
Is 18 years of age	Eligibility	9
age	PATO:0000011	15-18
Has a life expectancy of at least 12 weeks	Eligibility	10
Has laboratory values of:	Eligibility	11
White blood cell (WBC) count 3000 x 106/L Absolute neutrophil count (ANC) 1500 x 106/L Hemoglobin 9 g/dL Total bilirubin 1x upper limit of normal (ULN) AST and ALT 2.5 x ULN Alkaline phosphatase 2.5 x ULN; up to 5xULN if elevation is due to bone disease Serum creatinine 1.5 mg/dL Calculated creatinine clearance >50 mL/min (based on Cockroft and Gault method [Appendix III]) Platelet count 100,000 x 106/L	Eligibility	12
blood	UBERON:0000178	6-11
x	LABO:0000148	34-35
x	LABO:0000148	79-80
x	LABO:0000148	122-123
x	LABO:0000148	168-169
x	LABO:0000148	199-200
x	LABO:0000148	213-214
x	LABO:0000148	368-369
x	LABO:0000148	399-400
hemoglobin	CHEBI:35143	87-97
phosphatase	GO:0016791,BAO:0000295	183-194
bone disease	DOID:0080001	241-253
creatinine	CHEBI:16737	260-270
creatinine	CHEBI:16737	292-302
creatinine clearance	CMO:0000765	292-312
platelet count	CMO:0000029	376-390
If patient has had radiation therapy, it has been completed >3 weeks prior to the start of study treatment. NOTE: Previously irradiated lesions will not be evaluable. However, these patients will still be eligible.	Eligibility	13
patient	HADO:0000008,OAE:0001817	3-10
patient	HADO:0000008,OAE:0001817	182-189
Has a negative serum pregnancy test within 7 calendar days prior to registration (female patients of childbearing potential [not surgically sterilized and between menarche and 1 year postmenopause	Eligibility	14
female	PATO:0000383	82-88
menarche	GO:0042696	163-171
year	UO:0000036	178-182
If fertile, patient (male or female) has agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a period of 3 months thereafter	Eligibility	15
patient	HADO:0000008,OAE:0001817	12-19
male	CHEBI:30780,PATO:0000384	21-25
male	CHEBI:30780,PATO:0000384	31-35
female	PATO:0000383	29-35
duration	PATO:0001309	120-128
Has signed the most recent Patient Informed Consent Form	Eligibility	16
patient	HADO:0000008,OAE:0001817	27-34
Has signed a Patient Authorization Form Note: Having tissue available is not an inclusion criterion in this study; however, available tissue will be collected (see Section 8) if possible.	Eligibility	17
patient	HADO:0000008,OAE:0001817	13-20
tissue	UBERON:0000479	53-59
tissue	UBERON:0000479	134-140
Exclusion Criteria:	Eligibility	18
A patient will be excluded from this study if he or she meets any of the following criteria:	Eligibility	19
patient	HADO:0000008,OAE:0001817	2-9
excluded	HP:0040285	18-26
Had prior treatment with ixabepilone or other epothilones	Eligibility	20
ixabepilone	CHEBI:63605	25-36
Had prior radiation to 30% of major bone marrow containing areas (pelvis, lumbar spine)	Eligibility	21
bone marrow	UBERON:0002371	36-47
Has ER+ and/or PR+ disease that has not progressed on hormone therapy, unless the patient has life-threatening or rapidly progressing visceral disease	Eligibility	22
disease	DOID:4,OGMS:0000031	19-26
disease	DOID:4,OGMS:0000031	143-150
hormone	CHEBI:24621	54-61
patient	HADO:0000008,OAE:0001817	82-89
Has HER2+ disease (IHC staining of 3+ [uniform, intense membrane staining of >30% of invasive tumor cells]), a FISH result of more than 6 HER2 gene copies per nucleus or a FISH ratio (HER2 gene signals to chromosome 17 signals of >2.2)	Eligibility	23
disease	DOID:4,OGMS:0000031	10-17
membrane	GO:0016020	56-64
result	BAO:0000179	116-122
gene	BAO:0000582	143-147
gene	BAO:0000582	189-193
nucleus	CHEBI:33252,GO:0005634	159-166
ratio	UO:0000190	177-182
chromosome	GO:0005694	205-215
Has only lytic bone disease or nonmeasurable disease only	Eligibility	24
bone disease	DOID:0080001	15-27
disease	DOID:4,OGMS:0000031	20-27
disease	DOID:4,OGMS:0000031	45-52
Has a known, prior, severe (NCI CTCAE Grade 3-4) history of hypersensitivity reaction to a drug formulated in CremophorÂ®EL (polyoxyethylated castor oil) or has history of severe allergic reactions to cisplatin or other platinum-containing compounds	Eligibility	25
severe	HP:0012828	20-26
severe	HP:0012828	171-177
history	BFO:0000182	49-56
history	BFO:0000182	160-167
hypersensitivity	GO:0002524,DOID:1205	60-76
drug	CHEBI:23888	91-95
castor oil	CHEBI:140618	141-151
cisplatin	CHEBI:27899	200-209
Has been treated previously with a platinum-containing agent	Eligibility	26
Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy. Washout periods for these prior therapies are specified in Section 5.	Eligibility	27
Is receiving concurrent investigational therapy or has received such therapy within the 30 days prior to dosing Day 1	Eligibility	28
day	UO:0000033	91-94
day	UO:0000033	112-115
Has neuropathy (motor or sensory) >Grade 1	Eligibility	29
neuropathy	DOID:870	4-14
Has evidence of CNS involvement requiring radiation or steroid treatment. Patients with stable brain metastases who are off steroids at least 2 weeks are eligible.	Eligibility	30
steroid	CHEBI:35341	55-62
steroid	CHEBI:35341	124-131
stable	HP:0031915	88-94
brain	UBERON:0000955	95-100
Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection	Eligibility	31
Has clinically relevant coagulopathy either secondary to hepatic dysfunction or an underlying condition requiring therapeutic anticoagulation (specifically, A-fib, history of DVT). A daily aspirin or Plavix for CAD are permitted.	Eligibility	32
condition	PDRO:0000129	94-103
history	BFO:0000182	164-171
Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs	Eligibility	33
history	BFO:0000182	6-13
basal cell carcinoma	HP:0002671,DOID:2513	72-92
carcinoma	HP:0030731,DOID:305	83-92
carcinoma	HP:0030731,DOID:305	105-114
uterine cervix	UBERON:0000002	126-140
Is a pregnant or breast feeding woman	Eligibility	34
breast	UBERON:0000310	17-23
Is unable to comply with the requirements of the study	Eligibility	35
Outcome Measurement:	Results	0
Objective Response Rate (ORR)	Results	1
rate	BAO:0080019	19-23
Evaluate the objective response rate calculated as CR+ PR in the population evaluable for response, as well as the 2 subgroups (hormone receptor positive [ER+/PR+/HER2-, ER+/PR-/HER2-, ER-/PR+/HER2-]) and ER-/PR-HER2-, separately).	Results	2
rate	BAO:0080019	32-36
rate	BAO:0080019	223-227
hormone	CHEBI:24621	128-135
receptor	BAO:0000281	136-144
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	Results	3
target	BAO:0003064	76-82
target	BAO:0003064	157-163
target	BAO:0003064	249-255
diameter	PATO:0001334	237-245
Time frame: 24 months	Results	4
time	PATO:0000165	0-4
Results 1:	Results	5
Arm/Group Title: Triple Negative	Results	6
Arm/Group Description: ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle.	Results	7
ixabepilone	CHEBI:63605	59-70
carboplatin	CHEBI:31355	100-111
Overall Number of Participants Analyzed: 46	Results	8
Measure Type: Number	Results	9
Unit of Measure: percentage of participants  30.4        (17.7 to 45.8)	Results	10
Results 2:	Results	11
Arm/Group Title: HR Positive	Results	12
Arm/Group Description: ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle.	Results	13
ixabepilone	CHEBI:63605	95-106
carboplatin	CHEBI:31355	136-147
Overall Number of Participants Analyzed: 53	Results	14
Measure Type: Number	Results	15
Unit of Measure: percentage of participants  34        (21.5 to 48.3)	Results	16
Adverse Events 1:	Adverse Events	0
Total: 10/48 (20.83%)	Adverse Events	1
NEUTROPENIA 1/48 (2.08%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	0-11
THROMBOCYTOPENIA 0/48 (0.00%)	Adverse Events	3
thrombocytopenia	HP:0001873,DOID:1588	0-16
VOLUME BLOOD DECREASED 1/48 (2.08%)	Adverse Events	4
volume	PATO:0000918	0-6
blood	UBERON:0000178	7-12
FIBRILLATION ATRIAL 1/48 (2.08%)	Adverse Events	5
HYPOTENSION 1/48 (2.08%)	Adverse Events	6
hypotension	HP:0002615	0-11
ABDOMINAL PAIN 1/48 (2.08%)	Adverse Events	7
abdominal pain	HP:0002027	0-14
APPETITE DECREASED 0/48 (0.00%)	Adverse Events	8
DEHYDRATION 4/48 (8.33%)	Adverse Events	9
dehydration	HP:0001944	0-11
DIARRHEA 4/48 (8.33%)	Adverse Events	10
diarrhea	HP:0002014,DOID:13250	0-8
NAUSEA 3/48 (6.25%)	Adverse Events	11
nausea	HP:0002018	0-6
VOMITING 2/48 (4.17%)	Adverse Events	12
vomiting	HP:0002013	0-8
FEVER 1/48 (2.08%)	Adverse Events	13
fever	HP:0001945	0-5
RIGORS 0/48 (0.00%)	Adverse Events	14
rigors	HP:0025145	0-6
Adverse Events 2:	Adverse Events	15
Total: 5/53 (9.43%)	Adverse Events	16
NEUTROPENIA 1/53 (1.89%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	0-11
THROMBOCYTOPENIA 1/53 (1.89%)	Adverse Events	18
thrombocytopenia	HP:0001873,DOID:1588	0-16
VOLUME BLOOD DECREASED 0/53 (0.00%)	Adverse Events	19
volume	PATO:0000918	0-6
blood	UBERON:0000178	7-12
FIBRILLATION ATRIAL 0/53 (0.00%)	Adverse Events	20
HYPOTENSION 0/53 (0.00%)	Adverse Events	21
hypotension	HP:0002615	0-11
ABDOMINAL PAIN 0/53 (0.00%)	Adverse Events	22
abdominal pain	HP:0002027	0-14
APPETITE DECREASED 1/53 (1.89%)	Adverse Events	23
DEHYDRATION 0/53 (0.00%)	Adverse Events	24
dehydration	HP:0001944	0-11
DIARRHEA 0/53 (0.00%)	Adverse Events	25
diarrhea	HP:0002014,DOID:13250	0-8
NAUSEA 1/53 (1.89%)	Adverse Events	26
nausea	HP:0002018	0-6
VOMITING 1/53 (1.89%)	Adverse Events	27
vomiting	HP:0002013	0-8
FEVER 1/53 (1.89%)	Adverse Events	28
fever	HP:0001945	0-5
RIGORS 1/53 (1.89%)	Adverse Events	29
rigors	HP:0025145	0-6
